Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche
Mission Fulphila - Mylan-Biocon Biosimilar Neulasta Takes The Stage In US
GMP Lapses At Biocon’s Indian Site – Jitters for Neulasta Biosimilar Plans?
US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer
Sanofi's Admelog, a Humalog Follow-On, Approved In US As 'Black Hole' For Insulins Looms
Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
Evoke Pharma's Gimoti On Way To US FDA On 'Mixed' Data
MURANO To Drive AbbVie/Roche's Venetoclax In CLL


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts